GMTX

Gemini Therapeutics Inc

$1.56

chg

0.00 (0.00%)

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

1.16

52 wk hi

5.48

Cash

$119.1M

Burn Rate (Qtr)

$16.3M

Mkt Cap

$67.4m

Avg Volume

96,889

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

GMTX

BPIQ_Logo_RGB-01.jpg

Company Profile

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Recent Posts

See what the community is saying - click to see full post.